PMID- 34158112
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Jun 22
TI  - Individual heterogeneity screened umbilical cord-derived mesenchymal stromal 
      cells with high Treg promotion demonstrate improved recovery of mouse liver 
      fibrosis.
PG  - 359
LID - 10.1186/s13287-021-02430-6 [doi]
LID - 359
AB  - BACKGROUND: To investigate the heterogeneities of human umbilical cord 
      mesenchymal stromal cells (HUCMSCs) derived from different donors and their 
      therapeutic variations when applied to mouse liver fibrosis model. METHODS: The 
      characteristics of HUCMSCs derived from multiple donors were comprehensively 
      analyzed including expressions of surface markers, viability, growth curve, 
      karyotype analysis, tumorigenicity, differentiation potentials, and immune 
      regulation capability. Then, the HUCMSCs with distinct immunomodulatory effects 
      were applied to treat mouse liver fibrosis and their therapeutic effects were 
      observed. RESULTS: The HUCMSCs derived from multiple donors kept a high 
      consistency in surface marker expressions, viability, growth curve, and 
      tumorigenicity in nude mice but had robust heterogeneities in differentiation 
      potentials and immune regulations. In addition, three HUCMSC lines applied to 
      mice liver fibrosis model had different therapeutic outcomes, in line with 
      individual immune regulation capability. CONCLUSION: The HUCMSCs derived from 
      different donors have individual heterogeneity, which potentially lead to 
      distinct therapeutic outcomes in mouse liver fibrosis, indicating we could make 
      use of the donor-variation of MSCs to screen out guaranteed general indicators of 
      MSCs for specific diseases in further stromal cell therapy.
FAU - Xie, Yuanyuan
AU  - Xie Y
AD  - Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, 321 Zhongshan Road, Nanjing, 210000, People's Republic 
      of China.
FAU - Liu, Shuo
AU  - Liu S
AD  - Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, 321 Zhongshan Road, Nanjing, 210000, People's Republic 
      of China.
FAU - Wang, Liudi
AU  - Wang L
AD  - Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, 321 Zhongshan Road, Nanjing, 210000, People's Republic 
      of China.
FAU - Yang, Hui
AU  - Yang H
AD  - Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, 321 Zhongshan Road, Nanjing, 210000, People's Republic 
      of China.
FAU - Tai, Chenxu
AU  - Tai C
AD  - Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, 321 Zhongshan Road, Nanjing, 210000, People's Republic 
      of China.
FAU - Ling, Li
AU  - Ling L
AD  - Department of Endocrinology, University Health Science Center, Hua Zhong 
      University of Science and Technology Union Shenzhen Hospital and The 6th 
      Affiliated Hospital of Shenzhen, Shenzhen, 518052, Guangdong, People's Republic 
      of China.
FAU - Chen, Libo
AU  - Chen L
AD  - Department of Endocrinology, University Health Science Center, Hua Zhong 
      University of Science and Technology Union Shenzhen Hospital and The 6th 
      Affiliated Hospital of Shenzhen, Shenzhen, 518052, Guangdong, People's Republic 
      of China.
FAU - Liu, Shanshan
AU  - Liu S
AD  - Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing, 210000, People's Republic of China.
FAU - Wang, Bin
AU  - Wang B
AUID- ORCID: 0000-0003-3981-8849
AD  - Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing 
      University Medical School, 321 Zhongshan Road, Nanjing, 210000, People's Republic 
      of China. wangbin022800@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210622
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Liver Cirrhosis/therapy
MH  - *Mesenchymal Stem Cells
MH  - Mice
MH  - Mice, Nude
MH  - T-Lymphocytes, Regulatory
MH  - Umbilical Cord
PMC - PMC8220795
OTO - NOTNLM
OT  - Cell therapy
OT  - Differentiation
OT  - Heterogeneity
OT  - Immunomodulation
OT  - Liver fibrosis
OT  - Umbilical cord mesenchymal stromal cells
COIS- The authors declare that they have no competing interests.
EDAT- 2021/06/24 06:00
MHDA- 2021/07/13 06:00
PMCR- 2021/06/22
CRDT- 2021/06/23 05:48
PHST- 2021/02/13 00:00 [received]
PHST- 2021/06/05 00:00 [accepted]
PHST- 2021/06/23 05:48 [entrez]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2021/06/22 00:00 [pmc-release]
AID - 10.1186/s13287-021-02430-6 [pii]
AID - 2430 [pii]
AID - 10.1186/s13287-021-02430-6 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2021 Jun 22;12(1):359. doi: 10.1186/s13287-021-02430-6.